Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LivaNovaSTU:LIA -5.48%73 EV-to-FCF is 26.40 as of Jul. 15, 2026, which is 49% below its 10-year median of 51.27. GuruFocus rates STU:LIA with a GF Score™ of 73/100 and a GF Value™ of €54.59 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 414 Medical Devices & Instruments companies, LivaNova ranks worse than 54.83% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, LivaNova's Enterprise Value is €3,645 Mil.
LivaNova's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €138 Mil. Therefore, LivaNova's EV-to-FCF for today is 26.40.
The historical rank and industry rank for LivaNova's EV-to-FCF or its related term are showing as below:
STU:LIA'
s EV-to-FCF Range Over the Past 10 Years
Min: -41.61 Med: 51.27 Max: 408.48
Current: 25.77
During the past 13 years, the highest EV-to-FCF of LivaNova was 408.48. The lowest was -41.61. And the median was 51.27.
STU:LIA's EV-to-FCF is ranked worse than 54.83% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.695
vs STU:LIA: 25.77
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
LivaNova's share price for today is €69.00.
LivaNova's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.674.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
LivaNova EV-to-FCF Related Terms
LivaNova EV-to-FCF Historical Data
* Premium members only.
The historical data trend for LivaNova's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, LivaNova's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LivaNova EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LivaNova's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where LivaNova's EV-to-FCF falls into.
LivaNova's current Enterprise Value is €3,645 Mil.
LivaNova's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €138 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LivaNova (STU:LIA) has a EV-to-FCF of 26.40 as of Jul. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on LivaNova and its competitors. This is 49% below median its historical median of 51.27. According to the industry distribution chart, LivaNova ranks #227 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 54.8%.
Is LivaNova's EV-to-FCF too high?
LivaNova's current EV-to-FCF of 26.40 is 49% below median its 10-year median of 51.27. The Medical Devices & Instruments industry median EV-to-FCF is 23.70. LivaNova's value of 26.40 is 11.4% above this industry median. Based on the distribution chart, LivaNova ranks #227 out of 414 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, LivaNova has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does LivaNova's EV-to-FCF compare to IRTC and HAE?
According to the Medical Devices & Instruments industry distribution chart, LivaNova ranks #227 out of 414 companies for EV-to-FCF. This places LivaNova in the lower half of its industry. The industry median EV-to-FCF is 23.70. LivaNova's value of 26.40 is 11.4% above this benchmark. While the company's 10-year median is 51.27 vs. the industry median of 23.70, LivaNova has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.70, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LivaNova's current EV-to-FCF of 26.40 is 11.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on LivaNova and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LivaNova's current EV-to-FCF is 26.40, which is 49% below median its own 10-year median of 51.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LivaNova stock overvalued right now?
Based on GuruFocus' analysis, LivaNova (STU:LIA) is currently considered Modestly Overvalued. The stock's GF Value™ is €54.59, compared to a current price of €69.00 — trading 26.4% above its estimated fair value. The current EV-to-FCF is 26.40, which is 49% below median its 10-year median of 51.27 and 11.4% above the Medical Devices & Instruments industry median of 23.70. LivaNova's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For LivaNova (STU:LIA), the current EV-to-FCF is 26.40 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LivaNova (STU:LIA) Overvalued in 2026?
Based on GuruFocus' analysis, LivaNova stock appears to be overvalued.
The current stock price of €69.00 is trading 26.4% above its estimated GF Value™ of €54.59.
GuruFocus considers LivaNova to be Modestly Overvalued.
Key valuation signals for STU:LIA:
EV-to-FCF: 26.40 (49% below median its 10-year median of 51.27)
GF Value™: €54.59 vs. price of €69.00 (26.4% above fair value)
Industry Position: 11.4% above the Medical Devices & Instruments median (#227 of 414)
No single metric tells the full story. See the STU:LIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
73GF Score
Get the complete analysis for STU:LIA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:LIA has been successfully added to your 
